Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

May 29, 2009

Study Completion Date

January 30, 2013

Conditions
Esophageal Cancer
Interventions
DRUG

Induction Therapy - Capecitabine

Two 21-day cycles will be given as induction. Capecitabine will be given at 1000 mg/m2 twice daily approximately 12 hours apart for 14 days, followed by seven days off.

DRUG

Induction Therapy - Oxaliplatin

Two 21-day cycles will be given as induction. Oxaliplatin will be given at 70 mg/m2 intravenously in 5% dextrose over two hours on days 1 and 8 of each cycle.

DRUG

Combination Therapy - Capecitabine

Two 21-day cycles will be given for combination therapy. Capecitabine will be given at 825 mg/m2 twice daily approximately 12 hours apart for five days (Monday through Friday) followed by two days off for 51/2 weeks.

DRUG

Combination Therapy - Oxaliplatin

Two 21-day cycles will be given. Oxaliplatin will be given at 50 mg/m2 intravenously in 5% dextrose over two hours on days 1, 8 and 15 of each cycle.

RADIATION

Combination Therapy - Radiation

1.8 Gy daily Monday through Friday to a total of 50.4 Gy for 6 weeks during combination therapy.

PROCEDURE

Evaluation for response and surgery

Four to eight weeks following the completion of therapy subjects will undergo evaluation for response and surgical resection.

Trial Locations (1)

60611-3013

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

All Listed Sponsors
lead

Northwestern University

OTHER

NCT00711412 - Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer | Biotech Hunter | Biotech Hunter